Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Celltrion acquire Asian rights to cancer drug
On top of milestone payments which could reach $6 million, Igeneon will be entitled to receive royalties from sales of IGN311 in Asia, once the drug has received
On top of milestone payments which could reach $6 million, Igeneon will be entitled to receive royalties from sales of IGN311 in Asia, once the drug has received
Adacel is released following a decision by the Advisory Committee on Immunization Practices to recommend that such a tetanus-diphtheria-pertussis booster is given to all adolescents in the US.
The company is developing Viramidine in oral form for administration in combination with pegylated interferon for the treatment of chronic hepatitis C. Valeant is currently conducting two pivotal
Dr Ronald Lane, Bionutrics’ chairman and CEO stated, “This acquisition is an important step in the commercialization of Bionutrics’ drug technology and further execution of our business plan.”
“This study will provide us additional valuable information regarding the optimum dose range for testosterone suppression, an important outcome measure in the management of hormone-dependent prostate cancer,” stated
This is the first demonstration of the efficacy of short interfering RNA at therapeutically relevant doses, and the company believes the study results establish a strong scientific foundation
The mid-stage trial showed that Reverset was effective as an add-on medication in tandem with other treatments. At 16 weeks, patients treated with 200mg Reverset, alongside their standard
Human papillomavirus (HPV) is one of the most common sexually-transmitted infections worldwide and can cause genital warts, certain strains of the virus can lead to cervical cancer. In
The company has been encouraged to initiate the clinical phase of development by positive results in preclinical studies. XL820 has exhibited dose-dependent growth inhibition in models of breast
Under the terms of the agreements, P&GP will access a wide range of discovery and preclinical expertise offered by Evotec, ranging from assay development, screening, medicinal and computational